Related Experiment Video
Updated: Oct 14, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
Mimma Rizzo1, Patrizia Giannatempo2, Camillo Porta1,3
1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy.
Abstract:
In recent years, diagnostic and therapeutic advances have contributed to a reduction in mortality rates of patients with metastatic urothelial carcinoma (mUC). Immune checkpoint inhibitors have demonstrated efficacy and safety as both first-line and first-line switch maintenance therapy for mUC. For platinum-refractory patients, in addition to immunotherapy, other targeted agents (antibody-drug conjugates and fibroblast growth factor receptor inhibitors) have been approved after demonstrating a clinically relevant advantage in overall response rate, progression-free survival, and overall survival compared to standard of care. Sequential treatment strategies are finally feasible for patients with advanced urothelial carcinoma. This review will summarize the results of the most important phase II-III clinical trials for first-line, switch maintenance, second-line, and subsequent lines of therapy, and describe the most promising clinical trials currently ongoing in these treatment scenarios.
Insights
Advances in treating metastatic urothelial carcinoma (mUC) include immune checkpoint inhibitors and targeted therapies. Sequential treatment strategies are now feasible, improving patient outcomes.
Area of Science:
- Oncology
- Urothelial Carcinoma Research
- Clinical Trial Analysis
Background:
- Metastatic urothelial carcinoma (mUC) mortality rates are decreasing due to recent therapeutic advancements.
- Immune checkpoint inhibitors show efficacy in first-line and maintenance therapy for mUC.
- Targeted agents offer improved outcomes for platinum-refractory mUC patients.
Purpose of the Study:
- To review pivotal Phase II-III clinical trials in mUC treatment.
- To summarize efficacy of first-line, maintenance, and subsequent therapies.
- To highlight ongoing clinical trials for advanced urothelial carcinoma.
Main Methods:
- Systematic review of Phase II-III clinical trials.
- Analysis of data on immune checkpoint inhibitors and targeted agents.
- Evaluation of treatment strategies for mUC across different lines of therapy.
Main Results:
- Immune checkpoint inhibitors are effective in first-line and maintenance settings.
- Targeted agents like antibody-drug conjugates and FGFR inhibitors show significant advantages in platinum-refractory mUC.
- Sequential treatment approaches are viable and beneficial for advanced mUC.
Conclusions:
- Modern therapies have significantly improved mUC patient outcomes.
- A range of effective treatment options are available for mUC, including immunotherapy and targeted agents.
- Ongoing trials continue to explore novel therapeutic strategies for advanced urothelial carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Microorganisms in Medicine and Therapeutics